One of the triazole antifungal agents that inhibits cytochrome P-450-dependent enzymes resulting in impairment of ergosterol synthesis. It has been used against histoplasmosis, blastomycosis, cryptococcal meningitis & aspergillosis.
For the treatment of the following fungal infections in immunocompromised and non-immunocompromised patients: pulmonary and extrapulmonary blastomycosis, histoplasmosis, aspergillosis, and onychomycosis.
Local Institution - 0002, Atlanta, Georgia, United States
Local Institution - 0001, Lenexa, Kansas, United States
Research Site, Brooklyn, Maryland, United States
Parexel Baltimore - Early Phase Clinical Unit, Baltimore, Maryland, United States
ICON San Antonio Clinical Research Unit, San Antonio, Texas, United States
West China Hospital of Sichuan University, Chengdu, Sichuan, China
Yali Liu, Guangdong, Shantou, China
ICON Groningen Van Swietenlaan 6, Groningen, Netherlands
Q-Pharm, Herston, Queensland, Australia
Nucleus Network Pty Ltd, Melbourne, Victoria, Australia
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.